Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zicam Cold Remedy Nasal Spray is a homeopathic intranasal product marketed for the reduction of common cold duration and the relief of nasal congestion. Developed by Zicam (a brand owned by Church & Dwight), the current 'no-drip' formulation is zinc-free and plant-based, utilizing active ingredients such as *Galphimia glauca*, *Luffa operculata*, and *Sabadilla*. This formulation was established following the 2009 FDA warning regarding permanent anosmia (loss of smell) linked to previous zinc-gluconate-based Zicam nasal sprays. As a homeopathic remedy, it is prepared according to the Homeopathic Pharmacopoeia of the United States (HPUS) and is classified as an unapproved homeopathic drug. It is intended for use at the first sign of a cold and often includes inactive ingredients like menthol and eucalyptus for a cooling sensation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zicam Cold Remedy Nasal Spray.